BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 16, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/13 cls
Genmab (CSE:GEN) UBS Guillaume van Renterghem Upgrade Buy (from neutral) 0% DKK221.25
van Renterghem upgraded in anticipation of FDA acceptance and potential Priority Review of a BLA for Arzerra ofatumumab to treat chronic lymphocytic leukemia (CLL). He expects acceptance in the coming weeks and approval of the mAb against CD20 by year end. GlaxoSmithKline (LSE:GSK; NYSE:GSK) has exclusive worldwide rights.
Genzyme (NASDAQ:GENZ) Deutsche Bank Mark Schoenebaum Upgrade Buy (from hold) 6% $56.14
Schoenebaum thinks the shares, which have fallen more than 20% in the past month, have been oversold. While the Lumizyme delay and price control...

Read the full 765 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >